There were 22 pharmaceutical acquisitions in the second quarter of 2020, slightly below the average of 27.
The biggest deal so far has been Gilead’s acquisition of Forty Seven for $4.9 billion, significantly lower than the average largest deal, according to EvaluatePharma.
The five largest pharmaceuticals M&A deals this year:
- Gilead’s acquisition of Forty Seven — $4.9 billion
- Novo Nordisk’s acquisition of Corvidia — $2.1 billion
- Alexion’s acquisition of Portola — $1.4 billion
- Eli Lilly’s acquisition of Dermira — $1.1 billion
- Takeda’s divestiture of select drugs to Hypera Pharma — $825 million
More articles on pharmacy:
US sues Teva for alleged MS drug kickback scheme
J&J to acquire Momenta Pharma for $6.5B
White House adviser says Kodak execs made ‘dumbest decisions’ on government loan
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
